Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins

Y Katsuki, Yukio Katsuki, Yasunori Shibutani, Y Shibutani, Daisuke Aoki, D Aoki, Shiro Nozawa, S Nozawa
Cancer · 1997 · vol. 79(1) , pp. 169–176 · doi:10.1002/(sici)1097-0142(19970101)79:1<169::aid-cncr24>3.0.co;2-1 · PMID:8988742 · W2022921801
article OA: bronze CC0 ⤵ 17 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Dienogest demonstrated potent anticancer activity against hormone-dependent cancers at doses ineffective for progestins, acting differently by not suppressing uterine weight changes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Dienogest is a synthetic progestational steroid that is used for contraception. It is being studied for the treatment of endometriosis, but its anticancer activity remains unknown. The authors investigated the anticancer effect of dienogest on hormone-dependent cancers. METHODS: The authors used two cell lines derived from human endometrial carcinoma (HEC-88nu cells expressing estrogen receptors [ER] but not progesterone receptors [PR] and Ishikawa cells expressing both ER and PR) and a cell line derived from human breast carcinoma (MCF-7 cells expressing both ER and PR). The authors examined the in vivo antitumor activity and the antiuterotropic activity of dienogest in mice and compared it with the activity of several progestins. RESULTS: At oral doses of 0.01-1 mg/kg/day, dienogest significantly suppressed the 17 beta-estradiol benzoate (E2)-dependent tumor growth of HEC-88nu cells, which were unresponsive to known progestins such as medroxyprogesterone acetate (MPA, 100 mg/kg/day, administered orally) and norethisterone (NES, 100 mg/kg/ day, administered orally). The suppressive effect of dienogest on tumor growth was not diminished in the presence of excess MPA. Dienogest also suppressed the E2-dependent tumor growth of both Ishikawa and MCF-7 cells, both of which responded to MPA. However, the minimum effective dose of dienogest (0.01-1 mg/kg/day) was much lower than that of MPA (100 mg/kg/day). In contrast, dienogest did not suppress the E2-induced increase in uterine weight, whereas MPA and NES suppressed it significantly. CONCLUSIONS: Dienogest showed potent anticancer activity against hormone-dependent cancers at doses at which progestins show no activity.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antineoplastic Agents, Hormonal Breast Neoplasms Endometrial Neoplasms Hormone Antagonists Nandrolone Neoplasms, Hormone-Dependent Animals Antineoplastic Agents, Hormonal Breast Neoplasms Breast Neoplasms Drug Screening Assays, Antitumor Endometrial Neoplasms Endometrial Neoplasms Female Hormone Antagonists Humans Mice Mice, SCID Nandrolone Nandrolone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (21)

Cited by (17)

Source provenance

europepmc
last seen: 2026-06-20T06:14:18.781669+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:10:57.821266+00:00
License: CC0 · commercial use OK